REGENXBIO to Participate in Global Healthcare Conferences
September 07 2016 - 4:01PM
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company
focused on the development, commercialization and licensing of
recombinant adeno-associated virus (AAV) gene therapy based on its
proprietary NAV® Technology Platform, today announced that it will
participate in the Morgan Stanley Global Healthcare Conference on
Tuesday, September 13, 2016 in New York.
A live webcast of REGENXBIO’s presentation is scheduled to begin
at 12:55 p.m. ET and will feature a fireside chat with Kenneth T.
Mills, President and Chief Executive Officer. The live
webcast can be accessed in the Investors section of REGENXBIO’s
website at www.regenxbio.com. An archived replay of the
webcast will be available on the same website for approximately 30
days following the presentation.
REGENXBIO representatives will also attend the Bank of America
Merrill Lynch Global Healthcare Conference on Friday, September 16,
2016 in London to meet one-on-one with investors, analysts and
other potential corporate partners.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the
development, commercialization and licensing of recombinant
adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV®
Technology Platform, a proprietary AAV gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to
transform the lives of patients suffering from severe diseases with
significant unmet medical need by developing and commercializing in
vivo gene therapy products based on REGENXBIO's NAV Technology
Platform. REGENXBIO seeks to accomplish this mission through a
combination of internal development efforts and third-party NAV
Technology Platform licensees. As of June 30, 2016, REGENXBIO's NAV
Technology Platform was being applied in the development of 29
product candidates for a variety of diseases, including five
internally developed candidates and 24 partnered candidates
developed by REGENXBIO's licensees.
CONTACT:
Investors
Elizabeth Broder, 646-378-2945
ebroder@troutgroup.com
Media
Laura Bagby, 312-448-8098
lbagby@6degreespr.com
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Sep 2023 to Sep 2024